Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review

K Yang, ASW Oak, BE Elewski - American Journal of Clinical Dermatology, 2021 - Springer
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …

Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review

A Thatiparthi, A Martin, J Liu, A Egeberg… - American Journal of …, 2021 - Springer
The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs

ZE Holcomb, ML Porter, AB Kimball - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin
disorder characterized by nodules, abscesses, fistulae, and significant scarring in …

Biologic therapies for the treatment of hidradenitis suppurativa

M Rosales Santillan, PC Morss, ML Porter… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by
inflammatory nodules, abscesses, and fistulae. Patients tend to present in young adulthood …

Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant …

A Ion, AM Dorobanțu, LG Popa, MM Mihai, OA Orzan - Biology, 2022 - mdpi.com
Simple Summary Psoriasis is a chronic multisystem inflammatory disease associated with a
wide range of comorbidities including cardiovascular disease, hypertension, diabetes …

Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week …

W Lu, JF Wang, YJ Zhang, R Chang… - Clinical, Cosmetic and …, 2024 - Taylor & Francis
Introduction This study observed the effectiveness of ustekinumab and reactivation risk of
concurrent latent tuberculosis infection (LTBI) and inactive hepatitis B virus (HBV) infection …

[PDF][PDF] Risk of hepatitis B virus reactivation in patients on secukinumab for psoriasis: a series of 4 cases

LM Moneva-Leniz, A Sahuquillo-Torralba… - Actas Dermo …, 2020 - docusalut.com
Los pacientes psoriásicos en tratamiento con fármacos biológicos e historia de infección por
virus hepatitis B (VHB) tienen riesgo de reactivación viral 1. Con el fin de evaluar la …

Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database

J Wang, X Geng, X Zhang, Y Xiao… - Frontiers in …, 2022 - frontiersin.org
Background: Reports were recently published on hepatitis B virus reactivation (HBVr),
tuberculosis (TB), and atypical mycobacterial infection (AMI) in patients with ustekinumab …

[PDF][PDF] Dorobant, u, AM; Popa, LG; Mihai, MM; Orzan, OA Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of …

A Ion - 2022 - academia.edu
Psoriasis is a chronic multisystem inflammatory disease associated with a plethora of
comorbidities including metabolic syndrome, cardiovascular disease, hypertension …

Wirksamkeit und Sicherheit von systemischer Psoriasis-Therapie bei viraler Hepatitis, Diabetes mellitus oder Niereninsuffizienz. Systematische Reviews

RLA Jakubzyk - 2023 - refubium.fu-berlin.de
Einleitung Diabetes mellitus (DM), virale Hepatitis (VH) und Niereninsuffizienz (NI) stellen
häufige Komorbiditäten (KM) bei Patient* Innen mit Psoriasis vulgaris (PSO) dar. Der …